0001104659-26-048127
SEC filingZepp Health reported $258.9M in revenue for FY2025, with a gross margin of 38.3%, but incurred an operating loss of $29.2M and net loss of $40.1M — driven by the sharp decline in Xiaomi wearable sales and persistent fixed-cost structure.
Operating income was -$29.2M, resulting in an operating margin of -11.3%. The filing does not quantify prior-year operating income, but the magnitude of the loss signals that fixed costs — particularly research and development and general and administrative expenses — did not adjust proportionally to the revenue decline. Net income was -$40.1M, and diluted EPS was -$0.16. These figures incorporate all non-operating items and tax effects, confirming that the earnings shortfall stems from the full cost structure bearing down on a significantly smaller revenue base — not isolated one-time charges or accounting adjustments.
The business context packet explicitly states: 'The loss of, or a significant reduction in orders from, any key customer — whether due to changes in such customer’s business strategy, competitive dynamics, or other factors — could materially and adversely affect our revenues and results of operations.' FY2025 represents the realization of this risk. With no disclosure of new major customer wins or diversification milestones, the financial results underscore structural vulnerability to concentration — a condition acknowledged, not mitigated, in the narrative. No quantitative targets, transition timelines, or alternative revenue pathway details are provided in the authoritative or business context packets.